ClinicalTrials.gg
RecruitingNCT04739670BELLAUpdated Mar 1, 2024

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

A Phase 2 interventional study of Atezolizumab and Bevacizumab in Metastatic Triple Negative Breast Cancer, sponsored by Peter MacCallum Cancer Centre, Australia. Recruiting at 4 sites in Australia. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Peter MacCallum Cancer Centre, Australia · Phase 2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies testing atezolizumab in Triple Negative Breast Neoplasms — 3 open to participants now, 8 under way, 1 of them phase 3. atezolizumab · Triple Negative Breast Neoplasms.

Planned enrollment
23rd of 25
31 · median 106
Started
2021
with 2 others
Phase 2
13 of 25
3 open now
Registered
22nd of 25
by date

Among the 25 studies testing atezolizumab in Triple Negative Breast Neoplasms, this one is the 23rd largest by planned enrollment, is one of 3 that started in 2021, is one of 13 in phase 2, and was the 22nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

3 of the 25 studies testing atezolizumab in Triple Negative Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing atezolizumab in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

The study hypothesise that the combination of carboplatin, gemcitabine, bevacizumab and atezolizumab may be synergistic and improve outcomes for patients with early relapsed TNBC by overcoming mechanisms of immune resistance and thus potentiating greater and more durable responses to immune checkpoint inhibitor therapy. Early relapsing TNBC represents a high priority, unmet need whereby effective therapeutic strategies are urgently needed.

Read the detailed description

This is a multi-center, single arm phase II study designed to evaluate the efficacy and safety of atezolizumab plus bevacizumab plus carboplatin plus gemcitabine in patients with locally recurrent, inoperable or metastatic recurrent PD-L1 positive or stromal TIL positive TNBC (Triple Negative Breast Cancer).

Assessment of Programmed death-ligand 1 (PD-L1) status will be available centrally for patients in which PD-L1 testing or stromal TIL testing has not been performed or is not available. In such cases, patients will be required to sign a pre-screening consent form allowing collection and testing of archival tumour samples for PD-L1 status. Patient's that are PD-L1 positive and who fulfil the remaining study eligibility criteria will then be offered participation into the main BELLA study.

Following confirmation of eligibility and registration to the main study, patients will receive treatment as outlined in Table 1 until disease progression according to RECIST 1.1, unacceptable toxicity or patient withdrawal. In the absence of disease progression, the discontinuation of atezolizumab, bevacizumab, carboplatin or gemcitabine (owing to AEs) can occur independently. In the event of ongoing clinical benefit but disease progression, treatment continuation may occur if approved by the CPI.

Table 1:

Order Treatment Dose Dose Frequency Route of Administration

  1. Atezolizumab 1200 mg Day 1 of each 21 day cycle IV
  2. Bevacizumab 15 mg/kg Day 1 of each 21 day cycle IV
  3. Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle IV
  4. Carboplatin AUC 5 Day 1 of each 21 day cycle IV

Tumour response will be evaluated according to RECIST 1.1. Any evaluable and measurable disease must be documented at screening and re-assessed every 6 weeks from cycle 1 - day 1, regardless of any dose delays.

CT or MRI scans should include chest, abdomen, and pelvis. CT or MRI scans of the brain should be completed at screening and subsequently performed if clinically indicated. At the Investigator's discretion, CT or MRI scans may be repeated at any time if progressive disease is suspected. Imaging based assessments should always be completed rather than clinical assessment to determine response.

Patients who discontinue treatment for any reason will have an End of Treatment visit 30 days after the last dose of treatment after which, patients will move into the follow-up phase of the study where they will be assessed on a 3 monthly basis. Patients with progressive disease will be followed for survival only and patients who discontinue treatment for other reasons will be followed for progression and survival. All patients will be followed up for 2 years after the last patient has been commenced treatment.

There will be 31 patients recruited into the study. If a patient does not receive any protocol treatments for any reason, that patient will be replaced in the study. There are no requirements for follow-up on patients who do not commence treatment.

It is expected that it will take 24 months to accrue the required 31 evaluable patients. Patients will be followed up until 2 years after the last patient has commenced treatment.

Translational Research:

  1. Pre-treatment archival FFPE sample collected at pre-screening or screening for the main study will be tested retrospectively at the completion of the trial for

    Quantification of PD-L1 expression and Quantification of TILs on H\&E slides

  2. Two fresh tumour tissue samples to be collected if deemed clinically feasible by the investigator: an "on-treatment" tumour sample should be collected during cycle 1, days 15-21 and a "post-progression" tumour sample should be collected ≥ 14 days after the last dose of bevacizumab, and prior to commence of a new therapy. On-treatment FFPE sample will be tested for

    Quantification of PD-L1 expression Quantification of TILs on H\&E slides

  3. A whole blood sample will also be taken prior to the start of treatment, prior to day 1 of cycle 3, and at disease progression (EoT visit) for future research purposes for the assessment of biomarkers of immune activation in peripheral blood mononuclear cells.

Optional biomarker research:

  1. If the patient has consented to the Optional Biomarker Study, an additional whole blood sample will be taken on Cycle 1 Day 1 prior starting the treatment for germline whole-genome SNP genotyping to be performed retrospectively.
  2. If the patient has consented to the Optional Biomarker Study, stool samples for microbiome analysis will be collected prior to the start of treatment, prior to day 1 of cycle 3, and at disease progression (EoT visit). Microbiome analysis will be performed retrospectively.
03

Conditions studied

  • Metastatic Triple Negative Breast Cancer

Keywords

  • Triple Negative Breast Cancer
  • TNBC
  • Early relapse
  • immunotherapy
  • PD-L1
  • stromal TILs
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have provided written
  2. Male or female aged 18 years or over
  3. documented triple negative breast cancer (TNBC) that is locally advanced or and is not amenable to resection with curative intent Receptor status at study entry should correspond to the evaluation of the most recent as assessed locally TNBC for this study is defined as human epidermal growth factor receptor 2 ()-negative by ASCO-CAP 2018 guidelines, and estrogen receptor (ER) expression \< 10%, and progesterone receptor (PgR) expression \< 10%
  4. positive tumour or tumour-infiltrating lymphocyte-positive defined as:

    Immune cell PD-L1 expression ≥ 1% via SP142 assay via local or central lab OR Stromal TILs ≥ 5% by assessment on H\&E stained tumour sections via local laboratory Note: Where possible, local or central testing should be done on the most recently available tumour specimen and must have been obtained within 12 months prior to the date of consent.

  5. Documented disease progression (e.g., with biopsy sample, pathology, or imaging report) occurring within 12 months (\<12 months) from the last treatment with curative intent, which meets one of the following:

    Date of the last chemotherapy administration or Date of last curative intent radiation therapy or Date of the primary breast tumour surgery after neoadjuvant treatment, whichever occurred last

  6. Have not received prior chemotherapy or targeted systemic therapy for their locally advanced inoperable or metastatic recurrence Note: Prior radiation therapy for recurrent disease is permitted. There is no required minimum for radiation therapy; however, patients should have recovered from the effects of radiation prior to registration.
  7. , as defined by 1.1 Note: previously irradiated lesions may be considered as measurable disease only if disease progression has been unequivocally documented at that site since radiation.
  8. Availability of a representative FFPE tumour block (preferred) or at least 25 unstained slides collected within 12 months prior to registration Note: An FFPE block/slides will not be required for cases where tumour tissue was previously sent to the Central Laboratory for PD-L1 status testing in pre-screening following discussion with the CPI.

    Note: If a tumour sample taken within 12 months before registration is not available and a tumour biopsy is not clinically feasible, the primary surgical resection sample or the most recent FFPE tumour biopsy sample may be used.

    Note: Patients with fewer than 25 unstained slides (but no fewer than 17) may be eligible following discussion with the CPI.

  9. Patients with an performance status 0-1 (see Appendix 1)
  10. ≥ 12 weeks
  11. Adequate haematologic and end-organ function, defined by the following laboratory results obtained within 7 days prior to registration:

    ≥ 1.5x109/L (without G-CSF support within 2 weeks prior to registration) Lymphocyte count ≥ 0.5x109/L count ≥ 100x109/L (without transfusion within 2 weeks prior to registration) ≥ 80 g/L (patients may be transfused or receive erythropoietic treatment to meet this criterion)

    and ALT ≤ 2.5 x the , with the following exceptions:

    • Patients with documented liver metastases: AST and ALT ≤ 5× ULN Serum ≤ 1.5× ULN
    • Patients with known Gilbert's disease who have serum bilirubin level ≤ 3× ULN may be enrolled.

    Patients who are not receiving therapeutic anticoagulation: and aPTT ≤ 1.5× ULN. Patients who are receiving an anticoagulant medicinal product must be on a stable anticoagulant regimen and have an INR which is not above the target therapeutic range during the 7 days prior to registration Calculated ≥ 30 mL/min (Cockcroft-Gault formula; see Appendix 2).

  12. Women of must agree to remain abstinent (refrain from heterosexual intercourse) or use a method with a failure rate of ≤1% per year during the treatment period and for at least 6 months after the last dose of study treatment (see section 7.11.1.1)
  13. Women of child bearing potential must have a negative serum pregnancy test within 7 days prior to registration to the study
  14. Men must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agree to refrain from donating sperm as defined in section 7.11.1.2
  15. Patient is willing and able to comply with the protocol for the duration of the study including undergoing biopsies, treatment, and scheduled visits and examination including follow up

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from study entry:

  1. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to registration to study
  2. Symptomatic, untreated, or actively progressing . Patients with a history of treated CNS lesions are eligible, provided that all of the following criteria are met:

    Measurable or non-, per 1.1, must be present outside the CNS No history of intracranial haemorrhage or spinal cord haemorrhage are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord) There is no clinical or radiological evidence of interim progression between completion of CNS-directed therapy and the screening brain scan The patient has not received stereotactic radiotherapy within 7 days prior to registration to the study or whole-brain radiotherapy within 14 days prior to registration to the study The patient has no ongoing requirement for as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted Asymptomatic patients with CNS metastases newly detected at screening are eligible for the study after receiving radiotherapy or surgery, with no need to repeat the screening brain scan

  3. Grade ≥ 2 peripheral neuropathy
  4. History or presence of
  5. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) (patients with indwelling catheters such as PleurX® are allowed)
  6. Uncontrolled tumour-related pain Note: Patients requiring pain medication must be on a stable regimen at study entry. Symptomatic lesions (e.g. bone metastases or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to registration to the study. Patients should be recovered from the effects of radiation prior to registration. There is no required minimum recovery period. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g. epidural metastasis that is not presently associated with spinal cord compression) should be considered for loco-regional therapy, if appropriate, prior to registration to the study.
  7. Uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionised calcium or total calcium >3 mmol/L or corrected serum calcium > ) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy Note: Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of hypercalcaemia are eligible
  8. other than TNBC within 5 years prior to registration to the study, with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS rate ≥ 90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer)
  9. Significant cardiovascular disease, such as (NYHA) cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to registration, unstable arrhythmias, or unstable angina Note: Patients with a known \< 40% will be excluded Note: Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF 40-50% must be on a stable medical regimen that is optimised in the opinion of the treating physician, in consultation with a cardiologist if appropriate
  10. Presence of an abnormal that is clinically significant in the Investigator's opinion, including complete left bundle branch block, second or third-degree heart block, evidence of prior myocardial infarction, or > 470 ms demonstrated by at least two consecutive ECGs
  11. Severe infection requiring oral or IV antibiotics within 4 weeks prior to registration to the study, including but not limited to hospitalisation for complications of infection, bacteraemia, or severe pneumonia Note: patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or exacerbation) are eligible for the study
  12. Positive test at screening
  13. Patients with active (chronic or acute; defined as having a positive HBsAg test at screening) or Note: Patients with past HBV infection or resolved HBV infection (defined as the presence of HBc Ab and absence of HBsAg) are eligible. HBV DNA must be obtained in these patients prior to registration Note: Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
  14. Major surgical procedure within 4 weeks prior to registration to the study or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis Note: placement of central venous access catheter(s) (e.g. port or similar) is not considered a major surgical procedure and is therefore permitted
  15. Treatment with therapy within 28 days prior to registration
  16. Pregnant or lactating, or intending to become pregnant during or within 6 months after the last dose of study treatment
  17. Any other significant uncontrolled disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications. This includes significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)
  18. Poor peripheral venous access
  19. Known sensitivity to any component of atezolizumab, bevacizumab, carboplatin and/or gemcitabine Exclusion Criteria Related to Atezolizumab
  20. History of severe allergic, anaphylactic, or other reactions to chimeric or humanised antibodies or fusion proteins
  21. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
  22. History of disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, SLE, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with the following are eligible:

    History of autoimmune-related hypothyroidism on a stable dose of thyroid-replacement hormone Controlled Type 1 diabetes mellitus on a stable insulin dosing regimen

    Eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g. patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:

    Rash must cover less than 10% of body surface area Disease is well controlled prior to registration and only requires low potency topical steroids No acute exacerbations of underlying condition within the previous 12 months (not requiring PUVA, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral steroids)

  23. Prior allogeneic stem cell or solid organ transplantation
  24. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organising pneumonia (i.e. bronchiolitis obliterans, cryptogenic organising pneumonia), or evidence of active pneumonitis on screening chest CT scan Note: History of radiation pneumonitis in the radiation field (fibrosis) is permitted
  25. Active tuberculosis
  26. Receipt of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that a live, attenuated vaccine will be required during atezolizumab treatment or within 5 months after the last dose of atezolizumab
  27. Prior treatment with CD137 agonists, , or anti-PD-L1 therapeutic antibody or pathway targeting agents
  28. Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to registration
  29. Treatment with systemic corticosteroids or other systemic medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, mycophenolate and anti-TNF agents) within 2 weeks prior to registration, or anticipated requirement for systemic immunosuppressive medications during the trial Note: Patients who have received acute, low dose, systemic immunosuppressant medications (e.g. one-time dose of dexamethasone) may be enrolled in the study Note: The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension, and low dose supplemental corticosteroids (\<10 mg prednisone or equivalent) for adrenocortical insufficiency are allowed Exclusion Criteria Related to Bevacizumab
  30. Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) Note: Anti-hypertensive therapy to achieve these parameters is allowable
  31. Prior history of hypertensive crisis or hypertensive encephalopathy
  32. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to registration
  33. History of hemoptysis (≥ one-half teaspoon of bright red blood per episode) within 1 month prior to registration
  34. Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
  35. Current or recent (within 10 days prior to registration) use of aspirin (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and clostazol
  36. Current use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes that has not been stable for > 2 weeks prior to registration

    • The use of full-dose oral or parenteral anticoagulants is permitted as long as the or aPTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least 2 weeks prior to registration
    • Prophylactic anticoagulation for the patency of venous access devices is allowed
    • Prophylactic use of low-molecular-weight heparin (i.e., enoxaparin 40 mg/day) is permitted. Concomitant treatment with Direct Oral Anticoagulants is not recommended due to bleeding risks
  37. Core or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to registration
  38. History of abdominal or tracheosphageal fistula or gastrointestinal perforation within 6 months prior to registration
  39. Clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
  40. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
  41. Serious, non-healing wound, active ulcer, or untreated bone fracture
  42. Proteinuria, as demonstrated by urine dipstick or > 1.0 g of protein in a 24-hour urine collection Note: All patients with ≥ 2+ protein on dipstick urinalysis at screening must undergo a 24-hour urine collection and must demonstrate ≤ 1 g of protein in 24 hours
Terms in these criteria, in plain language(39)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (estimated)

Study arms

  • Experimental
    Atezolizumab, Bevacizumab, Gemcitabine and Carboplatin

    Atezolizumab 1200 mg Day 1 of each 21 day cycle IV, Bevacizumab 15 mg/kg Day 1 of each 21 day cycle IV, Gemcitabine 1000 mg/m2 Day 1 and 8 of each 21 day cycle IV, Carboplatin AUC 5 Day 1 of each 21 day cycle IV

    Drug: Atezolizumab · Drug: Bevacizumab · Drug: Gemcitabine · Drug: Carboplatin

Interventions

  • Atezolizumab is a monoclonal antibody of IgG1 isotype PD-L1. It is used across a number of tumour types, both as a single-agent and in combination with other therapies such as chemotherapy.

  • Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) which exerts its effect by inhibiting angiogenesis, a critical component of tumour growth and metastasis.

  • Gemcitabine is a type of chemotherapy drug

  • Carboplatin is platinum based chemotherapy drug

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS is measured from treatment commencement to the first progression by RECIST 1.1, or death from any cause, whichever occurs first.

    Time frame: Assessed after commencement of treatment, until the last registered patient has been followed up for 2 years.

Secondary outcomes

  1. Adverse events (AEs)

    AEs using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: Through completion of treatment, maximum 30 months

  2. Objective Response Rate(ORR)

    ORR, defined as the proportion of patients with an objective response (CR or PR) at any stage after commencement of treatment using RECIST 1.1 criteria

    Time frame: Through Study completion, until the last registered patient has been followed up for 2 years.

  3. Duration of response (DOR)

    DOR is the time between the date of first response (CR/PR per RECIST1.1) to the date of first progression per RECIST1.1. Patients who died without progression will be censored on the date of their last tumour assessment.

    Time frame: Through Study completion, until the last registered patient has been followed up for 2 years.

  4. Overall survival (OS)

    OS is the time from treatment commencement to the date of death due to any cause.

    Time frame: Through Study completion, until the last registered patient has been followed up for 2 years.

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Upon request, consideration by the Sponsor will be given to sharing reports and/or patient-level data with potential collaborators.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Sep 2025, 54 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 54 months is close to that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2021
First posted
Feb 5, 2021
StartActual
Mar 1, 2021
Primary completionEst.
Sep 2025
CompletionEst.
Sep 30, 2025
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04739670
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Mar 1, 2021
Primary completion
Sep 2025 (estimated)
Completion
Sep 30, 2025 (estimated)
Last update
Mar 1, 2024

Study contacts

Stephen Luen, Dr
Contact
stephen.luen@petermac.org
+61385595000
Prof Sherene Loi, Prof
Contact
sherene.loi@petermac.org
+61385595000
Stephen Luen, Dr
principal investigator · Peter MacCallum Cancer Centre, Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab · Gemcitabine · Carboplatin

Start the discussion